Associated Papers
Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review.
Cura Y et al.
Cancers, 2023
Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R et al.
British Journal of Clinical Pharmacology, 2019
Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale.
Fanciullino R et al.
Pharmacogenomics, 2015
Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.
Serdjebi C et al.
Expert Opinion on Drug Metabolism & Toxicology, 2015
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Rosmarin D et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2014
Human cytidine deaminase: a biochemical characterization of its naturally occurring variants.
Micozzi D et al.
International Journal of Biological Macromolecules, 2014
Pharmacogenetics for individualized cancer chemotherapy.
Efferth T et al.
Pharmacology & Therapeutics, 2005
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity.
Yue L et al.
Pharmacogenetics, 2003
Select a paper to view details